Clinical Trial Update: A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate [Phase 1]

View source ↗

Summary

Phase I study evaluating a recombinant vaccinia virus expressing prostate-specific antigen in adults with prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Recombinant vaccinia virus expressing prostate-specific antigen

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostatic Neoplasms | Phase 1 | Status: COMPLETED